Relay Therapeutics Announces Updated Interim Data for RLY-2608 Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
RLAY Stock | USD 4.20 0.30 6.67% |
Slightly above 67% of Relay Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Relay Therapeutics suggests that many traders are alarmed. Relay Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Relay Therapeutics' earnings reports, geopolitical events, and overall market trends.
Relay |
New interim data show 11.4-month median PFS in 2L patients with PI3K-mutated, HRHER2- metastatic breast cancer at RP2D percent confirmed ORR across all patients 67 percent in patients with kinase mutations at RP2D Data support planned initiation of 2L pivotal study in 2025 Next-generation triplet combination with atirmociclib initiated ribociclib triplet combination ongoing Relay Therapeutics to host a conference call today, December 11, at 7am ET SAN ANTONIO, Dec. 11, 2024
Read at finance.yahoo.com
Relay Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Relay Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Relay Therapeutics Fundamental Analysis
We analyze Relay Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Relay Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Relay Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Debt To Equity
Debt To Equity Comparative Analysis
Relay Therapeutics is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Relay Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Relay Therapeutics stock to make a market-neutral strategy. Peer analysis of Relay Therapeutics could also be used in its relative valuation, which is a method of valuing Relay Therapeutics by comparing valuation metrics with similar companies.
Peers
Relay Therapeutics Related Equities
APLS | Apellis Pharmaceuticals | 1.07 | ||||
IPSC | Century Therapeutics | 0.00 | ||||
DAWN | Day One | 0.87 | ||||
ARVN | Arvinas | 2.57 | ||||
PLRX | Pliant Therapeutics | 2.57 | ||||
NRIX | Nurix Therapeutics | 4.44 | ||||
BPMC | Blueprint Medicines | 4.87 | ||||
MLYS | Mineralys Therapeutics, | 5.75 | ||||
BDTX | Black Diamond | 6.40 | ||||
AMLX | Amylyx Pharmaceuticals | 7.94 | ||||
STOK | Stoke Therapeutics | 8.18 | ||||
EWTX | Edgewise Therapeutics | 8.20 | ||||
GLUE | Monte Rosa | 8.34 | ||||
CGEM | Cullinan Oncology | 8.73 | ||||
CCCC | C4 Therapeutics | 9.63 | ||||
FHTX | Foghorn Therapeutics | 10.89 | ||||
TERN | Terns Pharmaceuticals | 15.29 |
Additional Tools for Relay Stock Analysis
When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.